PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(03): 285-288
DOI: 10.1055/s-0042-1748798
Perspective

Access, Affordability, and Sustainability: Barriers to High-Quality Care in a High-Income Country

Toms Vengaloor Thomas 
1   Department of Radiation Oncology, University of Mississippi, Mississippi, United States
,
Aju Mathew
2   Department of Oncology, Malankara Orthodox Syrian Church Medical College Kolenchery, Kochi, Kerala, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Introduction

There is a perception among oncologists that the field of global oncology pertains only to matters related to low- and middle-income countries (LMICs). It stems from a perception that considers lack of access to cancer care and unaffordability of therapy as problems that plague the less affluent regions of the world. In this commentary, we aim to shed light on the fact that these issues do not respect the dichotomies of high-income versus low-income countries or the global north versus south.

When physicians from high-income countries were surveyed about the access to cancer medicines deemed essential by the World Health Organization, a large majority of them felt that these medicines, including immunotherapy, were universally accessible (i.e., no substantial out-of-pocket expense for >90% of patients).[1] Unfortunately, the inaccessibility and unaffordability of cancer care are profound even in high-income countries, although we perceive it as otherwise. This inaccurate fact stated by practicing oncologists makes it clear that their current understanding of the accessibility and affordability of cancer care as oncologists is faulty.

Almost 27 million (8.6%) Americans were still uninsured in 2016.[2] A large proportion of cancer survivors experience financial hardships due to cancer.[3] Even if we falsely assume that the out-of-pocket expense for the individual is marginal, the economic burden of cancer care is steadily rising. It is definitely not sustainable for the economy in the long run.



Publikationsverlauf

Artikel online veröffentlicht:
02. Juli 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Fundytus A, Sengar M, Lombe D. et al. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol 2021; 22 (10) 1367-1377
    CrossrefPubMedGoogle Scholar
  • 2 American Society of Clinical Oncology. The State of Cancer Care in America, 2017: a report by the American Society of Clinical Oncology. J Oncol Pract 2017; 13 (04) e353-e394
    CrossrefPubMedGoogle Scholar
  • 3 Gordon LG, Merollini KMD, Lowe A, Chan RJ. A systematic review of financial toxicity among cancer survivors: we can't pay the co-pay. Patient 2017; 10 (03) 295-309
    CrossrefPubMedGoogle Scholar
  • 4 Zafar SY, Peppercorn JM, Schrag D. et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 2013; 18 (04) 381-390
    CrossrefPubMedGoogle Scholar
  • 5 Royce TJ, Schenkel C, Kirkwood K, Levit L, Levit K, Kircher S. Impact of pharmacy benefit managers on oncology practices and patients. JCO Oncol Pract 2020; 16 (05) 276-284
    CrossrefPubMedGoogle Scholar
  • 6 Beyer KMM, Zhou Y, Laud PW. et al. Mortgage lending bias and breast cancer survival among older women in the United States. J Clin Oncol 2021; 39 (25) 2749-2757
    CrossrefPubMedGoogle Scholar
  • 7 Mahal BA, Chen YW, Muralidhar V. et al. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol 2017; 28 (05) 1098-1104
    CrossrefPubMedGoogle Scholar
  • 8 Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol 2004; 171 (04) 1504-1507
    CrossrefPubMedGoogle Scholar
  • 9 Yoo W, Kim S, Huh WK. et al. Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. PLoS One 2017; 12 (02) e0172548 DOI: 10.1371/journal.pone.0172548.
    CrossrefPubMedGoogle Scholar
  • 10 Albert A, Giri S, Kanakamedala M. et al. Racial disparities in tumor features and outcomes of patients with squamous cell carcinoma of the tonsil. Laryngoscope 2019; 129 (03) 643-654
    CrossrefPubMedGoogle Scholar
  • 11 Goodwin JS, Freeman JL, Mahnken JD, Freeman DH, Nattinger AB. Geographic variations in breast cancer survival among older women: implications for quality of breast cancer care. J Gerontol A Biol Sci Med Sci 2002; 57 (06) M401-M406
    CrossrefPubMedGoogle Scholar
  • 12 Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 2005; 14 (03) 590-595
    CrossrefPubMedGoogle Scholar
  • 13 Lin Y, Wimberly MC. Geographic variations of colorectal and breast cancer late-stage diagnosis and the effects of neighborhood-level factors. J Rural Health 2017; 33 (02) 146-157
    CrossrefPubMedGoogle Scholar
  • 14 Boby JM, Rajappa S, Mathew A. Financial toxicity in cancer care in India: a systematic review. Lancet Oncol 2021; 22 (12) e541-e549
    CrossrefPubMedGoogle Scholar
  • 15 Zafar SY. Financial toxicity of cancer care: it's time to intervene. J Natl Cancer Inst 2015; 108 (05) djv370 DOI: 10.1093/jnci/djv370.
    CrossrefPubMedGoogle Scholar
  • 16 Bernard DS, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol 2011; 29 (20) 2821-2826
    CrossrefPubMedGoogle Scholar
  • 17 Davidoff AJ, Erten M, Shaffer T. et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer 2013; 119 (06) 1257-1265
    CrossrefPubMedGoogle Scholar
  • 18 Ramsey S, Blough D, Kirchhoff A. et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 2013; 32 (06) 1143-1152
    CrossrefPubMedGoogle Scholar
  • 19 Hanratty B, Holland P, Jacoby A, Whitehead M. Financial stress and strain associated with terminal cancer–a review of the evidence. Palliat Med 2007; 21 (07) 595-607
    CrossrefPubMedGoogle Scholar
  • 20 Fenn KM, Evans SB, McCorkle R. et al. Impact of financial burden of cancer on survivors' quality of life. J Oncol Pract 2014; 10 (05) 332-338
    CrossrefPubMedGoogle Scholar
  • 21 Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 2014; 32 (04) 306-311
    CrossrefPubMedGoogle Scholar
  • 22 Patel MS, Reed DA, Loertscher L, McDonald FS, Arora VM. Teaching residents to provide cost-conscious care: a national survey of residency program directors. JAMA Intern Med 2014; 174 (03) 470-472
    CrossrefPubMedGoogle Scholar
  • 23 Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev 2020; 29 (07) 1304-1312
    CrossrefPubMedGoogle Scholar
  • 24 Clarke JL, Laskowski RJ, Coons C. et al. Proceedings of the Christiana Care Health System Value Institute Value Symposium. Am J Med Qual 2012; 27 (6, Suppl): 3S-20S
    CrossrefPubMedGoogle Scholar
  • 25 Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102 (09) 605-613
    CrossrefPubMedGoogle Scholar
  • 26 Lyu H, Xu T, Brotman D. et al. Overtreatment in the United States. PLoS One 2017; 12 (09) e0181970 DOI: 10.1371/journal.pone.0181970.
    CrossrefPubMedGoogle Scholar
  • 27 Schnipper LE, Smith TJ, Raghavan D. et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012; 30 (14) 1715-1724
    CrossrefPubMedGoogle Scholar
  • 28 Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol 2017; 14 (06) 381-390
    CrossrefPubMedGoogle Scholar
  • 29 Santos PMG, Mathis NJ, Lapen K. et al. Assessment of Guideline-Nonconcordant Radiotherapy in Medicare Beneficiaries With Metastatic Cancer Near the End of Life, 2015- 2017. JAMA Health Forum 2022; e214468-e214468
    CrossrefPubMedGoogle Scholar
  • 30 Woolhandler S, Himmelstein DU. Single-payer reform: the only way to fulfill the president's pledge of more coverage, better benefits, and lower costs. Ann Intern Med 2017; 166 (08) 587-588
    CrossrefPubMedGoogle Scholar
  • 31 Allan GM, Lexchin J. Physician awareness of diagnostic and nondrug therapeutic costs: a systematic review. Int J Technol Assess Health Care 2008; 24 (02) 158-165
    CrossrefPubMedGoogle Scholar
  • 32 Feldman LS, Shihab HM, Thiemann D. et al. Impact of providing fee data on laboratory test ordering: a controlled clinical trial. JAMA Intern Med 2013; 173 (10) 903-908
    CrossrefPubMedGoogle Scholar
  • 33 Institute of Medicine. 2013. Best Care at Lower Cost: The Path to Continuously Learning Health Care in America. Washington, DC: The National Academies Press. https://doi.org/10.17226/13444.
  • 34 Hahn C, Kavanagh B, Bhatnagar A. et al. Choosing wisely: the American Society for Radiation Oncology's top 5 list. Pract Radiat Oncol 2014; 4 (06) 349-355
    CrossrefPubMedGoogle Scholar
  • 35 Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin 2018; 68 (02) 153-165
    CrossrefPubMedGoogle Scholar
  • 36 Sachs R. Administration finalizes most-favored nation drug pricing rule at the last minute. Health Aff Blog 2020
    PubMedGoogle Scholar
  • 37 Butcher L. Price transparency. Hosp Health Netw. Jun 2014;88(6):32–7, 1.
    Google Scholar
  • 38 Nair R, Radhakrishnan VS, Mallath MK. Rituximab biosimilars for B-cell lymphomas: a decade of real-world experience from India. Lancet Haematol 2021; 8 (08) e548-e549
    CrossrefPubMedGoogle Scholar